Elanco Animal Health (NYSE:ELAN) Rating Increased to Buy at Argus

Elanco Animal Health (NYSE:ELAN) was upgraded by research analysts at Argus from a “hold” rating to a “buy” rating in a report released on Wednesday, MarketBeat.com reports. The firm presently has a $25.00 price objective on the stock. Argus’ price objective would suggest a potential upside of 14.89% from the company’s current price.

Several other equities research analysts have also recently weighed in on ELAN. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings restated a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Thursday, November 13th. Piper Sandler raised their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, August 11th. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $18.00 to $24.00 in a research note on Tuesday, October 7th. Finally, Stifel Nicolaus raised their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.88.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $21.76 on Wednesday. The firm has a 50-day moving average price of $20.68 and a two-hundred day moving average price of $16.87. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $23.09. The company has a market capitalization of $10.81 billion, a P/E ratio of 363.39, a P/E/G ratio of 2.91 and a beta of 1.71. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors have recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co raised its stake in shares of Elanco Animal Health by 190.0% during the third quarter. CANADA LIFE ASSURANCE Co now owns 350,334 shares of the company’s stock valued at $6,869,000 after acquiring an additional 229,519 shares during the last quarter. Woodline Partners LP increased its holdings in Elanco Animal Health by 15.1% in the third quarter. Woodline Partners LP now owns 3,669,503 shares of the company’s stock valued at $73,904,000 after purchasing an additional 480,318 shares during the period. Shelton Capital Management bought a new position in Elanco Animal Health during the 3rd quarter worth $346,000. Polymer Capital Management US LLC bought a new position in Elanco Animal Health during the 3rd quarter worth $257,000. Finally, Public Employees Retirement System of Ohio lifted its holdings in Elanco Animal Health by 0.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 153,739 shares of the company’s stock worth $3,096,000 after buying an additional 953 shares during the period. 97.48% of the stock is owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.